Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Integumen Debt Conversion

1 May 2019 11:00

RNS Number : 7356X
Venn Life Sciences Holdings PLC
01 May 2019
 

1 May 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Integumen plc ("Integumen") Debt Conversion - Related Party Transaction

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces, that following the approval of Integumen shareholders and under the terms of the Venn Debt Conversion Agreement the debt of £421,000 owed by Integumen, has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence, conditional upon admission.

Separate to this conversion, Venn has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the conversion shares referred to above, Venn will hold 30,071,428 ordinary shares.

Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumens broker so as to ensure an orderly market in the ordinary shares.

The debt conversion is a related party transaction for the purposes of Rule 13 of the AIM Rules for companies. As Tony Richardson is Integumens Chairman, the Chief Executive of Venn, and therefore is not considered to be independent for the purposes of considering and negotiating the Venn Debt Conversion Agreement. The Directors (other than Tony Richardson) consider, having consulted with Arden Partners plc, the Company's nominated adviser, that the terms of the Venn Debt Conversion Agreement and conversion by Venn are fair and reasonable in so far as its Shareholders are concerned.

 

Enquiries:

Venn Life Sciences Holdings plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners plc Tel: +44 (0)2076145900

John Llewellyn-Lloyd, Ruari McGirr, Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

 

 

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

 

"Venn Debt Conversion Agreement"

the agreement dated 11 April 2019 between (1) the Company and (2) Venn to convert the Venn Debt into the Venn Debt Shares

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSASUFFUSEEI
Date   Source Headline
12th Dec 20194:41 pmRNSForm 8.3 - Open Orphan PLC
11th Dec 20194:03 pmRNSForm 8.3 - Open Orphan
11th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 201911:13 amGNWForm 8.3 - Open Orphan
11th Dec 20197:00 amRNSForm 8 (OPD)
10th Dec 20194:43 pmRNSForm 8 (DD) Open Orphan plc
10th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
10th Dec 20199:59 amPRNForm 8.3 - Open Orphan
10th Dec 20197:00 amRNSRule 2.9 Announcement
9th Dec 20191:27 pmRNSTotal Voting Rights
9th Dec 201912:21 pmPRNForm 8.3 - Open Orphan Plc
9th Dec 20197:00 amRNSRecommended All-Equity Offer
25th Nov 20197:00 amRNSEarly adopters signed for Genomic Health DataBANK
18th Nov 20197:00 amRNSContract signed with Carna Bioscience
15th Nov 20197:00 amRNSJefferies 2019 London Healthcare Conference
11th Nov 20197:00 amRNSPreferred Partner Agreement
24th Oct 20197:00 amRNSValue the Markets Webinar
21st Oct 20197:00 amRNSInvestor Event Attendance and Presentation
15th Oct 20197:00 amRNSAgreement signed with Empiric Logic
8th Oct 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Oct 20193:58 pmRNSResult of AGM
1st Oct 201911:08 amRNSHolding(s) in Company
27th Sep 20198:00 amRNSEuronext Growth Dublin Notice
25th Sep 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
23rd Sep 20193:39 pmRNSExercise of Warrants and Issue of Shares
16th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
12th Sep 20197:00 amRNSNotice of AGM
10th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
9th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
3rd Sep 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Sep 20197:00 amRNSUpcoming Investor Events
1st Aug 20197:00 amRNSDirectorate Changes
30th Jul 20198:00 amRNSEuronext Growth Dublin Notice
25th Jul 20197:00 amRNSExercise of Warrants and Issue of Shares
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
12th Jul 20197:00 amRNSIntegumen Shares
9th Jul 20195:26 pmRNSHolding(s) in Company
28th Jun 20198:00 amRNSEuronext Growth Dublin Notice
28th Jun 20197:59 amRNSEuronext Growth Dublin Cancellation Notice
28th Jun 20197:00 amRNSFirst Day of Dealings and Re-admission
25th Jun 20191:24 pmRNSDirectorate Update
14th Jun 201912:13 pmRNSEuronext Growth - Schedule One
14th Jun 201911:00 amRNSSchedule One - Ven Life Sciences Holdings plc
11th Jun 20197:30 amRNSEuronext Growth Dublin Market Restoration Notice
11th Jun 20197:30 amRNSRestoration - Venn Life Sciences Holding Plc
11th Jun 20197:01 amRNSPlacing of Shares
11th Jun 20197:00 amRNSAudited Final Results
10th May 20197:30 amRNSEuronext Growth Dublin Suspension Notice
10th May 20197:30 amRNSSuspension - Venn Life Sciences Holdings Plc
10th May 20197:01 amRNSConditional Acquisition of Open Orphan DAC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.